Avatrombopag
35 interactions 1 explained in plain English 249 cited references
Also sold as:
Doptelet
Doptelet®
About Avatrombopag
Avatrombopag is used to treat thrombocytopenia (a low number of platelets [type of blood cell needed for blood clotting]) in people with chronic (ongoing) liver disease who are scheduled to have a medical or dental procedure to help prevent bleeding complications. It is also used to treat thrombocytopenia in people wit… Read the full Avatrombopag drug information page →
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
· Updated Jul 12, 2026
· Editorial policy
· Data sources
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Most serious with:
Ensitrelvir
Abametapir
Apalutamide
Avacopan
Letermovir Injection
Fluorouracil Topical
Contraindicated
Avatrombopag Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects DetailsMajor
Avatrombopag Abametapir Explained Increased exposure of CYP3A4 substrate Details Avatrombopag Apalutamide Erleada Reduced CYP3A4/CYP2C9 substrate exposure Details Avatrombopag Avacopan Tavneos Increased CYP3A4 substrate exposure Details Avatrombopag Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Avatrombopag Carbamazepine Carbatrol Reduced CYP3A4/CYP2C9 substrate exposure and reduced efficacy of CYP3A4/CYP2C9 substrate Details Avatrombopag Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Avatrombopag Conivaptan Vaprisol Increased CYP3A substrate exposure Details Avatrombopag Deutivacaftor Increased CYP2C9 substrate exposure Details Avatrombopag Doxifluridine Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Avatrombopag Enzalutamide Xtandi Decreased avatrombopag exposure Details Avatrombopag Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Avatrombopag Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Avatrombopag Fexinidazole An increased CYP3A4 substrate exposure Details Avatrombopag Fluconazole Diflucan Increased avatrombopag exposure Details Avatrombopag Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Avatrombopag Itraconazole Sporanox Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Avatrombopag Letermovir Prevymis Increased CYP3A substrate exposure Details Avatrombopag Mifepristone Korlym Increased CYP3A4 substrate exposure Details Avatrombopag Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Avatrombopag Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Avatrombopag Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Avatrombopag Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Avatrombopag Rifampin Rifadin Decreased avatrombopag exposure Details Avatrombopag Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Avatrombopag Tegafur Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Avatrombopag Voriconazole Vfend Increased CYP3A4/CYP2C9 substrate exposure and an increased of CYP3A4/CYP2C9 substrates-related adverse effects Details Avatrombopag Fluorouracil Injection Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Avatrombopag Fluorouracil Topical Carac Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Avatrombopag Letermovir Injection Prevymis Increased CYP3A substrate exposure DetailsModerate
Avatrombopag Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Avatrombopag Kratom Increased CYP3A substrate exposure Details Avatrombopag Mavacamten Camzyos Reduced CYP3A4/CYP2C9 substrate exposure and reduced efficacy of CYP3A4/CYP2C9 substrate Details Avatrombopag Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Avatrombopag Sparsentan Filspari Reduced CYP2C9 substrate exposure and reduced efficacy of CYP2C9 substrate DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacistEducational information only, not medical advice. Always confirm interactions with your pharmacist
or prescriber before making any change to your medications.